Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medtronic plc (NYSE: MDT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, giving investors and analysts a detailed view of its financial condition, capital structure, governance, and material events. As an issuer with ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, Medtronic files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and specialized forms such as Form 25 for the removal from listing of specific debt securities.
Medtronic’s Form 8-K filings cover topics such as quarterly financial results, debt offerings, redemptions of senior notes, amendments to its Memorandum and Articles of Association, changes in board composition and executive roles, and other material definitive agreements. For example, recent 8-Ks describe euro-denominated senior notes due 2030 and 2045, their guarantees by Medtronic plc and affiliates, and the use of proceeds to repay existing notes. Other current reports document National Coverage Determinations, financial guidance updates, and dividend-related actions referenced in company news releases.
The company’s proxy statements (DEF 14A) outline its corporate governance structure, director elections, executive compensation programs, and shareholder proposals, including amendments to Articles of Association and capital reduction measures under Irish law. Form 25 filings relate to the delisting of specific classes of guaranteed senior notes once they are redeemed or otherwise withdrawn from the exchange, and do not affect the listing of MDT ordinary shares.
On this page, Stock Titan pairs Medtronic’s filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand items such as new debt issuances, changes in capital structure, or governance amendments. You can review 10-K and 10-Q reports for segment performance and risk disclosures, scan 8-Ks for notable events, and monitor registration statements and S-1 filings, such as the proposed IPO of the MiniMed diabetes business, to follow Medtronic’s strategic and financial decisions over time.
John P. Groetelaars filed an initial Form 3 reporting his relationship to Medtronic plc (MDT) as a Director and stating that he does not beneficially own any ordinary shares as of the event date 08/19/2025. The filing indicates it was submitted by one reporting person and was signed on behalf of Groetelaars by an attorney-in-fact, Patricia Walesiewicz. The form fulfills Section 16(a) reporting requirements for an insider initial ownership statement and contains an explicit declaration that no securities are beneficially owned.
John P. Groetelaars filed an initial Form 3 reporting his relationship to Medtronic plc (MDT) as a Director and stating that he does not beneficially own any ordinary shares as of the event date 08/19/2025. The filing indicates it was submitted by one reporting person and was signed on behalf of Groetelaars by an attorney-in-fact, Patricia Walesiewicz. The form fulfills Section 16(a) reporting requirements for an insider initial ownership statement and contains an explicit declaration that no securities are beneficially owned.
Medtronic plc reported that it issued a press release announcing its first quarter fiscal year 2026 financial results, which is provided as an exhibit to this report. The company also expanded its Board of Directors from 11 to 13 members and appointed John Groetelaars and William Jellison as new directors, effective August 19, 2025.
Mr. Jellison will serve on newly created Growth and Operations board committees, while Mr. Groetelaars will serve on the Growth committee. Both will be eligible for the standard non‑employee director cash retainer and equity grant described in Medtronic’s recent proxy materials. The company states there are no reportable related‑party transactions or selection arrangements involving either new director. The earnings and director appointment press releases are included as Exhibits 99.1 and 99.2.
Medtronic plc reported that it issued a press release announcing its first quarter fiscal year 2026 financial results, which is provided as an exhibit to this report. The company also expanded its Board of Directors from 11 to 13 members and appointed John Groetelaars and William Jellison as new directors, effective August 19, 2025.
Mr. Jellison will serve on newly created Growth and Operations board committees, while Mr. Groetelaars will serve on the Growth committee. Both will be eligible for the standard non‑employee director cash retainer and equity grant described in Medtronic’s recent proxy materials. The company states there are no reportable related‑party transactions or selection arrangements involving either new director. The earnings and director appointment press releases are included as Exhibits 99.1 and 99.2.